Edwards oximetry central venous catheter continuously monitors central venous oxygen saturation (Scv02), an early indicator of compromised or inadequate oxygen delivery. By providing a more sensitive indicator of oxygen imbalance, Edwards oximetry central venous catheter identifies critical changes earlier than traditional vital signs and intermittent sampling— enabling you to recognize and prevent tissue hypoxia sooner. 1-5
Edwards oximetry
central venous catheter
Continuous ScvO2 monitoring – The clarity in an early warning of oxygen imbalance.
Edwards oximetry central venous catheter – the first proven central venous catheter with continuous ScvO2 monitoring – reveals the true adequacy of tissue oxygenation for clarity in early assessment and intervention.1–5
Edwards oximetry central venous catheter with integrated Oligon†† antimicrobial protection (For use in the U.S. only)
Edwards oximetry central venous catheter
Helps guide therapy and provide real-time insight into the efficacy of intervention.1,2,6
Continuous ScvO2 monitoring enables proactive management of tissue hypoxia:1–5
- Reveals the root cause of oxygen imbalance, enabling you to determine appropriate therapy early.1,7
- Allows for immediate assessment of patient’s clinical response to therapy.1,2,6
- Helps you stay ahead of tissue hypoxia and stages of sepsis.8–11
Convenient, accurate and easy to use
- Uses same insertion techniques as that of central lines.
- Offers continuous ScvO2 monitoring, pressure monitoring and fluid resuscitation.
- Provides accurate oxygenation status.1
Edwards oximetry central venous catheter brochure
Model numbers
| Lumens | Length (CM) | Oligon | |
|---|---|---|---|
| X3816KT | 3 | 16 | |
| X3820KT | 3 | 20 | |
| XA3816KT | 3 | 16 | X |
| XA3816SAFKT | 3 | 16 | X |
| XA3820KT | 3 | 20 | X |
| XA3820SAFKT | 3 | 20 | X |
The advantages of antimicrobial protection and high-pressure injection, together in a single device.
Integrated Oligon antimicrobial protection
Continuous ScvO2 monitoring is also available with integrated Oligon antimicrobial†† material, which releases silver ions (Ag+) from an integrated polymer that will not wash away like antimicrobial coatings. Integrated Oligon antimicrobial material provides enduring antimicrobial protection. Silver ions (Ag+) are released at a stable rate to attack microbes, alter cell DNA and disrupt cell reproduction.
- Protects against gram-negative and gram-positive bacteria, fungi and resistant microorganism strains.12–14
High-pressure injection capability with the Edwards oximetry central venous catheter is indicated for high-pressure injection of high-contrast media for visualization under imaging modalities such as CT, MRI, and fluoroscopy.12 (For use with Oligon models only)
Edwards Oximetry central venous catheter with integrated Oligon†† antimicrobial protection (For use in the U.S. only)Early assessment with real-time ScvO2 monitoring enables proactive clinical decisions for your high-risk patients.1–5
Continuous ScvO2 monitoring is key to assessing the adequacy of the balance of oxygen delivery and consumption. The goal of continuous ScvO2 monitoring with the Edwards oximetry central venous catheter is to bring into balance the relationship between oxygen delivery and consumption to help improve the care of high-acuity patients.17
Demonstrated prognostic value of continuous ScvO2 monitoring can be seen in:
- Post-op high-risk surgeries18
- Trauma4
- Sepsis19
- Cardiac failure in congenital heart failure5
- Recovery in cardiac arrest20,21
Continuous ScvO2 monitoring has multiple applications in intra- and post-op stages including:22,23
- Risk for high blood loss, such as hepatic resections, trauma, vascular cases
- High fluid shifts in gastrointestinal cases
- Toleration of single-lung ventilation in thoracic procedures
- Early indication of failure to tolerate extubation
Edwards Lifesciences hemodynamic monitoring solutions offer advanced flow-based parameters to help you detect sepsis early, guide treatment evaluation, and comply with NQF/CMS bundle requirements.
Compatible Monitoring Platforms
Related Products
References:
- Reinhart K, et al. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med. 2004;30(8):1572-8.
- Rivers EP, et al. Central venous oxygen saturation monitoring in the critically ill patient. Curr Opin Crit Care. 2001;7(3):204-11.
- Ingelmo P, et al. Importance of monitoring in high risk surgical patients. Minerva Anestesiol. 2002;68(4):226-30.
- Scalea, TM, et al. Central venous oxygen saturation: a useful clinical tool in trauma patients. J Trauma 1990;30(12):1539-43.
- Ander, DS, et al. Undetected cardiogenic shock in patients with congestive heart failure presenting to the emergency department. Am J Cardiol 1998;82(7):888-91.
- Tweddell, JS, et al. Mixed venous oxygen saturation monitoring after stage 1 palliation for hypoplastic left heart syndrome. Ann Thorac Surg 2007;84:1301-1311
- Zaja J. Venous oximetry. Signa Vitae 2007;2(1):6-10.
- Spenceley, N., et al. Continuous central venous saturations during pericardial tamponade case report. Pediatr Crit Care Med 2007,Vol. 8,No. 3,p18.2.153.
- Krahn, G., et al. Early clinical evaluation of the Edwards PediaSat™ oximetry catheter in pediatric patients. Pediatr Crit Care Med 2007,Vol. 8,No. 3,p18.2.152.
- Spenceley, N., et al. Continuous central venous saturation monitoring in pediatrics: a case report. Pediatr Crit Care Med 2008, Vol. 9, No. 2, p e13-e16
- Lemson et al. Advanced hemodynamic monitoring in critically ill patients. Pediatrics. 2011
- GOV FDA 510k EOCVC (K160645)
- Edwards Oligon Oximetry Catheters contain an integrated Oligon antimicrobial material. The activity of the antimicrobial agent is localized at the catheter surfaces and is not intended for treatment of systemic infections. In vitro testing demonstrated that the Oligon material provided broad-spectrum effectiveness (= 3 log reduction from initial concentration within 48 hours) against the organisms tested: Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Enterococcus faecalis, Candida albicans, Escherichia coli, Serratia marcescens, Acinetobacter calcoaceticus, Corynebacterium diphtheriae, Enterobacter aerogenes, GMRSa, Pseudomonas aeruginosa, Candida glabrata and VRE (Enterococcus faecium).
- US Patent #4411648
- Ranucci M, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med 2003;31(1):52-9.
- Garcia, R, et al. Three years experience in implementing HICPAC recommendations for the reduction of central venous catheter-related bloodstream infections. Poster presentation at National APIC meeting, June 2003.
- Loren D. Continuous venous oximetry in surgical patients. Ann Surg. 1986;203/3:329-333.
- Pearse, R, et al. Changes in central venous saturation after major surgery, and association with outcome. Crit Care 2005;9(6):R694-91.
- Rady, MY, et al. Resuscitation of the critically ill in the ED: responses of blood pressure, heart rate, shock index, central venous oxygen saturation, and lactate. Am J Emerg Med 1996;14(2):218-25.
- Rivers, EP, et al. The clinical implications of continuous central venous oxygen saturation during human CPR. Ann Emerg Med 1992;21(9):1094-101.
- Nakazawa, K, et al. Usefulness of central venous oxygen saturation monitoring during cardiopulmonary resuscitation. A comparative case study with end-tidal carbon dioxide monitoring. Intensive Care Med 1994;20(6):450-1.
- Noguiera P, et al. Central Venous Saturation: A Prognostic Tool in Cardiac Surgery Patients. J Intensive Care Med. 2010;25(2):111-116.
- Vallet B, et al. Venous oxygen saturation as a physiologic transfusion trigger. Crit Care. 2010;14:213.
- Donati A, et al. Goal-directed intraoperative therapy reduces morbidity and length of hospital stay in high-risk patients. Chest. 2007;132:1817-1824.
- Marik P, et al. Does central venous pressure predict fluid responsiveness? A systemic review of the literature and the Tale of Seven Mares. Chest. 2008;134;172–178
